Somatostatin analogues for ADPKD: ending the confusing story of mGFR and eGFR.

Authors

Ron T Gansevoort, Thomas Bais

Published in

Kidney international. Volume 110. Issue 4. Pages 792-795.

Abstract

This commentary discusses the Lanreotide In Polycystic kidney disease Study (LIPS) that is published in this issue of Kidney International. It represents the last randomized evaluation of somatostatin analogues in patients with autosomal dominant polycystic kidney disease. Lanreotide did not demonstrate a beneficial effect on the primary outcome, measured glomerular filtration rate decline, but did suggest an effect on creatinine-estimated glomerular filtration rate slope. The discrepancy between both outcomes highlights important challenges in the interpretation of kidney function end points and statistical modeling. All in all, the findings of the LIPS trial support the current Kidney Disease: Improving Global Outcomes recommendation not to prescribe somatostatin analogues solely to preserve kidney function in autosomal dominant polycystic kidney disease.

PMID:
42760021
Bibliographic data and abstract were imported from PubMed on 19 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.